NCT04592211View on ClinicalTrials.gov

Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

May 31, 2026

Conditions
Gastric Cancer Stage IV
Interventions
DRUG

olaparib+pembrolizumab+paclitaxel

olaparib, 100\~200mg, PO, bid, continuous Pembrolizumab 200mg, IV, q 3 weeks Paclitaxel 80mg/m2 IV, Q weekly

Trial Locations (1)

Unknown

RECRUITING

Severance Hospital, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER